Amedeo Smart

Free Medical Literature Service

 

Amedeo

Ophthalmology
  Free Subscription

Articles published in
Lancet
    April 2024
  1. WILENIUS M, Jernman J, Hietaharju A, Salonen T, et al
    Swollen eyelids caused by polyvinylpyrrolidone histiocytosis with intravenous methylphenidate.
    Lancet. 2024;403:1574-1575.
    >> Share

    March 2024
  2. CAMPOCHIARO PA, Avery R, Brown DM, Heier JS, et al
    Gene therapy for neovascular age-related macular degeneration by subretinal delivery of RGX-314: a phase 1/2a dose-escalation study.
    Lancet. 2024 Mar 27:S0140-6736(24)00310-6. doi: 10.1016/S0140-6736(24)00310.
    >> Share

  3. RAKOCZY EP
    The promise of long-term treatment for neovascular age-related macular degeneration.
    Lancet. 2024 Mar 27:S0140-6736(24)00428-8. doi: 10.1016/S0140-6736(24)00428.
    >> Share

  4. EMMI G, Bettiol A, Hatemi G, Prisco D, et al
    Behcet's syndrome.
    Lancet. 2024;403:1093-1108.
    >> Share

  5. BROWN DM, Boyer DS, Do DV, Wykoff CC, et al
    Intravitreal aflibercept 8 mg in diabetic macular oedema (PHOTON): 48-week results from a randomised, double-masked, non-inferiority, phase 2/3 trial.
    Lancet. 2024 Mar 7:S0140-6736(23)02577-1. doi: 10.1016/S0140-6736(23)02577.
    >> Share

  6. LANZETTA P, Korobelnik JF, Heier JS, Leal S, et al
    Intravitreal aflibercept 8 mg in neovascular age-related macular degeneration (PULSAR): 48-week results from a randomised, double-masked, non-inferiority, phase 3 trial.
    Lancet. 2024 Mar 7:S0140-6736(24)00063-1. doi: 10.1016/S0140-6736(24)00063.
    >> Share

  7. CHEW EY
    Increasing concentrations of intravitreal therapies for neovascular age-related macular degeneration.
    Lancet. 2024 Mar 7:S0140-6736(24)00229-0. doi: 10.1016/S0140-6736(24)00229.
    >> Share

  8. GABRIELLE PH, Creuzot-Garcher C
    Can high-dose aflibercept satisfy unmet treatment needs in diabetic macular oedema?
    Lancet. 2024 Mar 7:S0140-6736(23)02760-5. doi: 10.1016/S0140-6736(23)02760.
    >> Share

    January 2024
  9. CYPERS G, Tsitsi P
    Retinitis pigmentosa and pes cavus in PHARC-polyneuropathy, hearing loss, ataxia, retinitis pigmentosa, and cataract-syndrome in a 62-year-old man.
    Lancet. 2024;403:391.
    >> Share

  10. SPEKREIJSE L, van den Biggelaar F, Nuijts R
    Equity, access, and carbon cost-effectiveness of bilateral cataract surgery - Authors' reply.
    Lancet. 2024;403:354.
    >> Share

  11. LIN JC, Greenberg PB
    Equity, access, and carbon cost-effectiveness of bilateral cataract surgery.
    Lancet. 2024;403:353.
    >> Share

  12. TING DSJ, Buchan JC
    Equity, access, and carbon cost-effectiveness of bilateral cataract surgery.
    Lancet. 2024;403:353-354.
    >> Share

  13. CHAKER L, Cooper DS, Walsh JP, Peeters RP, et al
    Hyperthyroidism.
    Lancet. 2024 Jan 23:S0140-6736(23)02016-0. doi: 10.1016/S0140-6736(23)02016.
    >> Share

    October 2023
  14. HEIER JS, Lad EM, Holz FG, Rosenfeld PJ, et al
    Pegcetacoplan for the treatment of geographic atrophy secondary to age-related macular degeneration (OAKS and DERBY): two multicentre, randomised, double-masked, sham-controlled, phase 3 trials.
    Lancet. 2023;402:1434-1448.
    >> Share

  15. CHEW EY
    Complement inhibitors for the treatment of geographic atrophy.
    Lancet. 2023;402:1396-1398.
    >> Share

    September 2023
  16. JAYARAM H, Kolko M, Friedman DS, Gazzard G, et al
    Glaucoma: now and beyond.
    Lancet. 2023 Sep 21:S0140-6736(23)01289-8. doi: 10.1016/S0140-6736(23)01289.
    >> Share

    June 2023
  17. PETRUSHKIN H, Solebo AL
    Imaging inflammation in early-onset sarcoidosis: granulomatous anterior uveitis in a 7-year-old girl.
    Lancet. 2023;401:1963.
    >> Share

    May 2023
  18. DMUCHOWSKA DA, Obuchowska I, Konopinska J
    Immediate versus delayed sequential bilateral cataract surgery.
    Lancet. 2023 May 15:S0140-6736(23)00692-X. doi: 10.1016/S0140-6736(23)00692.
    >> Share

  19. SPEKREIJSE L, Simons R, Winkens B, van den Biggelaar F, et al
    Safety, effectiveness, and cost-effectiveness of immediate versus delayed sequential bilateral cataract surgery in the Netherlands (BICAT-NL study): a multicentre, non-inferiority, randomised controlled trial.
    Lancet. 2023 May 15:S0140-6736(23)00525-1. doi: 10.1016/S0140-6736(23)00525.
    >> Share

  20. CONRAD N, Misra S, Verbakel JY, Verbeke G, et al
    Incidence, prevalence, and co-occurrence of autoimmune disorders over time and by age, sex, and socioeconomic status: a population-based cohort study of 22 million individuals in the UK.
    Lancet. 2023 May 5:S0140-6736(23)00457-9. doi: 10.1016/S0140-6736(23)00457.
    >> Share

    March 2023
  21. GUYMER RH, Campbell TG
    Age-related macular degeneration.
    Lancet. 2023 Mar 27:S0140-6736(22)02609-5. doi: 10.1016/S0140-6736(22)02609.
    >> Share

    December 2022
  22. CICINELLI MV, Buchan JC, Nicholson M, Varadaraj V, et al
    Cataracts.
    Lancet. 2022 Dec 21:S0140-6736(22)01839-6. doi: 10.1016/S0140-6736(22)01839.
    >> Share

    September 2022
  23. BOWMAN SJ, Dorner T, Mariette X, Luo WL, et al
    Ianalumab in Sjogren's syndrome: what can we learn from lupus trials? - Authors' reply.
    Lancet. 2022;400:808-809.
    >> Share

  24. DYBALL S, Parker B, Bruce IN
    Ianalumab in Sjogren's syndrome: what can we learn from lupus trials?
    Lancet. 2022;400:807-808.
    >> Share

    August 2022
  25. BAGENAL J, Khanna R, Hawkes S
    Not misogynistic but myopic: the new women's health strategy in England.
    Lancet. 2022 Aug 10. pii: S0140-6736(22)01486.
    >> Share

    January 2022
  26. WYKOFF CC, Abreu F, Adamis AP, Basu K, et al
    Efficacy, durability, and safety of intravitreal faricimab with extended dosing up to every 16 weeks in patients with diabetic macular oedema (YOSEMITE and RHINE): two randomised, double-masked, phase 3 trials.
    Lancet. 2022 Jan 21. pii: S0140-6736(22)00018.
    >> Share

  27. HEIER JS, Khanani AM, Quezada Ruiz C, Basu K, et al
    Efficacy, durability, and safety of intravitreal faricimab up to every 16 weeks for neovascular age-related macular degeneration (TENAYA and LUCERNE): two randomised, double-masked, phase 3, non-inferiority trials.
    Lancet. 2022 Jan 21. pii: S0140-6736(22)00010.
    >> Share

  28. CHIA MA, Keane PA
    Beyond anti-VEGF: can faricimab reduce treatment burden for retinal disease?
    Lancet. 2022 Jan 21. pii: S0140-6736(22)00105.
    >> Share

  29. SARAUX A, Devauchelle-Pensec V
    Primary Sjogren's syndrome: new beginning for evidence-based trials.
    Lancet. 2022;399:121-122.
    >> Share

  30. BOWMAN SJ, Fox R, Dorner T, Mariette X, et al
    Safety and efficacy of subcutaneous ianalumab (VAY736) in patients with primary Sjogren's syndrome: a randomised, double-blind, placebo-controlled, phase 2b dose-finding trial.
    Lancet. 2022;399:161-171.
    >> Share

  31. KAMOI K, Uchimaru K, Tojo A, Watanabe T, et al
    HTLV-1 uveitis and Graves' disease presenting with sudden onset of blurred vision.
    Lancet. 2022;399:60.
    >> Share

    October 2021
  32. AYADI K, Gallaoui S, Ben Nsir A
    Pituitary apoplexy, but not as we thought: a xanthogranuloma rather than an adenoma.
    Lancet. 2021;398:e16.
    >> Share


Free Medical Abstracts
Privacy Policy
Sponsors
Share

© Amedeo 1997-2016